v3.26.1
Segment Reporting
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company has determined that it has two operating segments which are aggregated into a single reportable segment- Drug Product, located in a single geographic location – the United States.
The Company’s Chief Executive Officer is the Chief Operating Decision Maker (“CODM”). The CODM manages the Company’s business activities as a single reportable segment. The CODM uses consolidated profit and loss to evaluate and measure performance against progress in its commercialization efforts and clinical trials. The following table sets forth significant segment expenses.
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Research and development:
Employee and contracted employee expense$2,621 $1,270 $4,959 $2,370 
Other research and development4,063 1,172 8,937 3,265 
Total research and development6,684 2,442 13,896 5,635 
Selling and marketing
Employee and contracted employee expense$7,506 $3,194 $14,806 $5,258 
Other selling and marketing4,941 3,190 10,173 5,600 
Total selling and marketing expense12,447 6,384 24,979 10,858 
General and administrative
Employee and contracted employee expense$9,429 $5,875 $19,957 $12,718 
Other general and administrative5,656 3,629 16,848 6,479 
Total general and administrative expense15,085 9,504 36,805 19,197 
Total operating expenses$34,216 $18,330 $75,680 $35,690 
The CODM also reviews revenue by major product line. The following table presents the disaggregation of revenue by major product line and revenue type for the three and six months ended June 30, 2026 and 2025:
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Product Sales:
DefenCath$66,119 $39,736 $163,630 $78,818 
Melinta Portfolio28,222 - 52,627 - 
Total Product Sales, net94,341 39,736 216,257 78,818 
Contract Revenue4,966 - 8,048 - 
Grant Income2,624 - 5,053 - 
Total Revenue and Grant Income101,931 39,736 229,358 78,818